Technology

Art

Study Finds Variability in Performance of FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio Test for Alzheimer Disease

;

5d ago· 5 min readenInsight

science health

Summary

This cross-sectional study evaluates the clinical performance of the FDA-cleared Lumipulse plasma p-tau217/β-amyloid 1-42 ratio test for detecting amyloid pathology in Alzheimer disease. The study assessed the manufacturer-recommended cut points across different clinical cohorts and found significant variability in sensitivity and specificity. The results suggest that the recommended cut points may not perform consistently across diverse patient populations, highlighting the need for careful validation and potential adjustment of thresholds in clinical practice.

Source

bskyStudy Finds Variability in Performance of FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio Test for Alzheimer Diseasedoi.org

Key quotes

· 3 pulled

The manufacturer-recommended cut points for the Lumipulse p-tau217/β-amyloid 1-42 ratio showed variable clinical performance across different study cohorts.

These findings highlight the importance of validating cut points in the intended use population before implementing this test in clinical practice.

The variability in sensitivity and specificity raises concerns about the generalizability of the FDA-cleared cut points to diverse patient populations.

Snippet from the RSS feed

This cross-sectional study evaluates the performance of the US Food and Drug Administration–cleared phosphorylated tau 217 (p-tau217) to β-amyloid 42 ratio cut points used to detect amyloid pathology associated with Alzheimer disease.

You might also wanna read

The Case for Amyloid Centiloid Quantification in Dementia Diagnosis

This Viewpoint article argues for moving beyond binary (positive/negative) reporting of amyloid PET scans in patients with mild cognitive im

ja.ma·4d ago

Científicos españoles logran localizar por primera vez los microtrombos que agravan el alzhéimer

Infobae·1d ago

NIH-funded study finds circular RNA blood test outperforms leading diagnostic for predicting Alzheimer's progression

A new NIH-funded study has identified circular RNAs (circRNAs) in the blood as a novel biomarker for Alzheimer's disease. Elevated levels of

nih.gov·6d ago

FDA Approves First Blood Test to Aid in Alzheimer’s Diagnosis, Giving Families a Head Start on Care Planning

ltcnews.com·1y ago

Novel Blood-Brain Barrier Modulation Strategy Shows Promise for Alzheimer's Treatment Through Enhanced Amyloid-β Clearance

This scientific research presents a novel therapeutic approach for Alzheimer's disease that targets the blood-brain barrier (BBB) to enhance